Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001791917-26-000005
Filing Date
2026-05-13
Accepted
2026-05-13 11:07:52
Documents
1
X0202

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 23690
  Complete submission text file 0001791917-26-000005.txt   25659
Mailing Address 8 DAVIS DRIVE SUITE 220 DURHAM NC 27713
Business Address 8 DAVIS DRIVE SUITE 220 DURHAM NC 27713 248-681-9815
Opus Genetics, Inc. (Subject) CIK: 0001228627 (see all company filings)

EIN.: 113516358 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-79996 | Film No.: 26971754
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 1751 RIVER RUN, SUITE 400 FORT WORTH TX 76107
Business Address 1751 RIVER RUN, SUITE 400 FORT WORTH TX 76107 817.984.9197
BIOS Fund III, LP (Filed by) CIK: 0001791917 (see all company filings)

EIN.: 843385883 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A